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Abstract
The AKT/PI3K/mTOR pathway is frequently altered in a range of human tumours, including bladder cancer. Here we report
the phenotype of mice characterised by deletion of two key players in mTOR regulation, Pten and Lkb1, in a range of tissues
including the mouse urothelium. Despite widespread recombination within the range of epithelial tissues, the primary
phenotype we observe is the rapid onset of bladder tumorigenesis, with median onset of approximately 100 days. Single
deletion of either Pten or Lkb1 had no effect on bladder cell proliferation or tumour formation. However, simultaneous
deletion of Lkb1 and Pten led to an upregulation of the mTOR pathway and the hypoxia marker GLUT1, increased bladder
epithelial cell proliferation and ultimately tumorigenesis. Bladder tissue also exhibited characteristic features of epithelial-
mesenchymal transition, with loss of the epithelial markers E-cadherin and the tight junction protein ZO-1, and increases in
the mesenchymal marker vimentin as well as nuclear localization of epithelial-mesenchymal transition (EMT) regulator Snail.
We show that these effects were all dependent upon mTOR activity, as rapamycin treatment blocked both EMT and
tumorigenesis. Our data therefore establish clear synergy between Lkb1 and Pten in controlling the mTOR pathway within
bladder epithelium, and show that loss of this control leads to the disturbance of epithelial structure, EMT and ultimately
tumorigenesis.
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Introduction
Deregulation of the PI3K pathway has been implicated in a
range of human epithelial tumours. Both Pten and Lkb1 play
fundamental roles in regulating this pathway, and mutations of
both genes are associated with neoplasia. Mechanistically, Pten
suppresses the PI3K pathway by dephosphorylating phosphatidy-
linositol-3, 4, 5-trisphosphates (PIP3) [1,2]. PIP3 production causes
Akt recruitment to the plasma membrane with subsequent Akt
phosphorylation at Thr308 and Ser473 [3]. Phosphorylated Akt
can then inhibit TSC2 with the subsequent activation of Rheb,
mTOR, S6K p70 and stimulation of protein synthesis and cell
growth [4]. Lkb1 also regulates mTOR via the TSC1/TSC2
complex as Lkb1 normally phosphorylates AMPK [5], for which
TSC2 is a substrate [6]. Germline mutation of PTEN, LKB1 or
TSC1/2 are all associated with human tumorigenesis (Cowden
syndrome, Peutz-Jeghers syndrome and tuberous sclerosis respec-
tively), and it is notable that all three syndromes share
characteristic features, particularly an increased predisposition to
hamartoma development [7].
Bladder cancer is one the most common neoplasias worldwide
[8], being more prevalent amongst white males and people who
have been exposed to cigarette smoke or industrial chemicals
[9,10]. Almost all bladder cancers originate in the bladder
epithelium (urothelium). At the time of diagnosis, bladder
carcinoma is often non-invasive (superficial bladder cancers) and
the tumors are confined to the mucosa or submucosa: and only 20
percent of bladder cancer cases have signs of local invasion and 3
percent have distant spread) [11]. However, the disease is able to
progress as has been documented by histological follow up of non-
invasive bladder cancer patients [12].
Recently, it has been suggested that epithelial-mesenchymal
transition (EMT) may be critical for the progression of cancer [13].
During EMT cells lose adherence and tight junctions, exhibit
changes in their cytoskeletal architecture, and they can break
through the basal membrane and become metastatic [14]. These
characteristics are broadly similar to the features associated with
cells undergoing EMT during normal development [13]. EMT
can be induced by a variety of different pathways, including TGF-
beta [15], Wnt [16], Notch [17], integrin [18] and also AKT/
PI3K/mTOR. For example, transfection of a constitutively active
form of the p110 catalytic subunit of PI3K has been reported to
induce loss of ZO-1 from tight junctions [19]; and cell lines
expressing constitutively active Akt show increased motility and
invasion, loss of cell-cell adhesion and reduced expression of E-
cadherin [20]. Furthermore, inhibition of mTOR by rapamycin
has been shown to decrease the invasive behavior of cells, such as
following TGF-b induced EMT [21].
One of the most important inducers of EMT and tumour
metastasis is hypoxia [22] and there is growing evidence of a
complex interplay between the AKT/PI3K/mTOR pathway and
hypoxia [23–28]. For example, hypoxia suppresses energy-costly
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mediated mTOR inhibition [24] or other mechanisms [25,26].
Correspondingly, TSC2 deletion abolishes hypoxia induced cell
cycle arrest and enhances cell proliferation [24]. Hypoxia is well
recognized to be capable of inducing EMT in cancer cells and this
can be prevented by PI3K inhibition [23]. Furthermore,
rapamycin treatment can coincidentally suppress mTOR signal-
ling, HIF-1a expression and tumorigenesis in Lkb12/+ tumours
[28].
AKT/PI3K/mTOR pathway alterations are very frequent in
bladder cancer, with 73% of human bladder tumours charac-
terised by alterations in one of the major pathway components:
TSC1, PI3K (PIK3CA) or PTEN [29]. More than half of all the
bladder tumours show loss of an allele of TSC1 [30]. PTEN
expression has been reported to be reduced in 49% of tumours,
and 25% are reported to be characterised by mutation of PIK3CA
[29]. AKT1 mutations also can be involved in bladder cancer
development [31] as well as germ line genetic variants in
RAPTOR [32]. Furthermore, these pathway mutations are often
not mutually exclusive, suggesting that they can have synergistic or
additive effects upon tumorigenesis [29].
Although loss of heterozygosity at the PTEN locus is a very
common event in muscle-invasive transitional cell carcinomas of
the bladder [33], previous attempts to generate mouse models
based upon Pten deficiency have shown rather mild phenotypes,
varying from an incidence of 10% of transitional cell carcinomas
[34] to no tumorigenesis at all [35,36]. However, combinatorial
mutation of both mouse Pten and p53 has been reported to result
in invasive neoplasia [36].
These observations suggest that single mutations of the AKT/
PI3K/mTOR pathway may be insufficient to drive bladder
tumorigenesis, reflecting a capacity of the pathway to compensate
for such single mutations. Lkb1 kinase is a tumour suppressor
which regulates the TSC1/2 complex [6], which is often
deregulated in human bladder cancer [29]. Thus, although Lkb1
is not been reported to be frequently mutated in this disease [29],
it is clear that pathways governed by Lkb1 are relevant to disease
and we therefore decided to evaluate the extent of in vivo synergy
between mutations in Pten and Lkb1 within murine epithelia.
To achieve this, we analysed the phenotypes of loss of either or
both Lkb1 and Pten from a range of mouse epithelia using a
conditional AhCre-LoxP strategy. The overriding phenotype of
these mice was of rapid onset of bladder EMT and neoplasia, both
of which we show to be dependent upon MTOR activity. Our
data therefore establish tissue specific synergy for these mutations
in both EMT and ultimately tumorigenesis.
Materials and Methods
Ethics Statement
All animal work was performed in accordance with the UK
Animal Scientific Procedures Act 1986 and was covered by both
Project and Personal licences that were issued by the Home Office
and reviewed by the Cardiff University Research Ethics
Committee. Professor Alan R Clarke Project Licence numbers
30-2246 (2005–2010) and 30/2737 (years 2010–2015), as well as
Dr Boris Shorning Personal Licence 60/8372 covered all
procedures and breeding.
Experimental Animals and Cre recombinase Induction
All experiments were conducted according to U.K. Home
Office regulations. Mice were maintained on C57BL6/J-129/Ola-
C3H outbred background and all mice were genotyped by PCR
using DNA extracted with Puregene DNA extraction kit (Gentra
systems), the primers were as described for the targeted Rosa26R
[37], Lkb1
fl/fl [38], Pten
fl/fl [39] and AhCreER
TM transgene [40].
Cre recombinase activity was induced in all mice (both in
AhCreER
TM -negative and AhCreER
TM -positive) by 4 intraper-
itoneal injections of 80 mg/kg beta-naphthoflavone combined
together with 80 mg/kg of Tamoxifen (both were dissolved in corn
oil). The mice received 4 injections in 2 days with a 12 hour span
between each injection. All times indicated in the text were related
to the time elapsed since the first exposure. Mice were sacrificed
and dissected at a certain timepoint or to avoid unnecessary
suffering. Their bladders were removed and measured with a fine
calliper.
b-Galactosidase analysis
Mouse bladder samples from 14 day induced animals were
opened out, rinsed with cold water and fixed with pins on a wax
plate. Following a quick fix in 2% formaldehyde/PBS/0.1%
glutaraldehyde, bladders were demucified and left to stain in X-gal
solution overnight as described for the intestinal samples in [36].
The recombination was assessed by blue staining in the tissue
[40,41].
Western analysis
Bladder epithelium (from animals 50 days post induction) was
peeled off the bladder wall, homogenized and solubilised in 500 ml
of lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, 5 mM EDTA,
5 mM EGTA, 0.5% NP-40, 40 mM beta-glycerolphosphate,
0.5 mg/ml each Leupeptin, Pepstatin, Chymostatin, 50 mM
NaF, 5 mM Na3VO4, with 1 mM microcystin) for 10–20 minutes
on ice. Supernatants were aliquoted and snap frozen in liquid
nitrogen. Protein concentrations were determined using a
Coomassie based method (Bio-Rad). Equal amounts of cellular
protein (20 mg) were separated on 10% acrylamide gel and
subsequently transferred on Hybond ECL nitrocellulose mem-
brane (Amersham Biosciences). Total protein was visualized with
Ponceau (Sigma). After blocking the membranes in TBS
containing 5% BSA, 0.05% Tween 20, and 0.02% NaN3 for
1 hour, primary antibodies were added in block solution for
overnight incubation at 4uC. After five repeated five minute
washes in TBS, 0.05% Tween 20, the appropriate HRP-
conjugated secondary donkey antibodies (Amersham Biosciences)
were added (dilution 1:5000) for 30 minutes. After five washes (five
minutes each) antibody binding was detected using ECL
reagent (Amersham Biosciences). The sources and dilutions of
the primary antibodies used for western blotting analysis are
mouse monoclonal Lkb1, 1:1000, from Upstate (clone5c10), rabbit
polyclonal Pten, phospho-AMPK
T172, phospho-mTOR
S2448,
phospho-S6
S240/244, phospho-IRS
S302, 1:1000, all from Cell
Signalling, mouse monoclonal beta-actin, 1:5000, from Sigma,
rabbit polyclonal Raptor
Ser722, 1:500, from Millipore.
Immunohistochemistry and immunofluorescence
Immunohistochemistry and immunofluorescence were per-
formed on formalin fixed tissue. Bladders were opened, rinsed
with water, and fixed without inflation in ice-cold 10% neutral
buffered formalin for a maximum of 14 hours at 4uC. All fixed
samples were embedded in paraffin and sectioned to 5–6 mmo n
poly L-lysine slides. Antigen retrieval was performed by boiling in
citrate buffer (LabVision) for 10 minutes at 100uC. For the
immunohistochemical procedure we blocked endogenous perox-
idase by EnVision blocking solution (DakoCytomation) for 5
minutes. The non-specific binding was blocked for 30 minutes
with either 5% goat serum (DakoCytomation) for the primary
rabbit polyclonal antibodies or 5% rabbit serum (DakoCytoma-
Lkb1 and Pten Suppress EMT and Tumorigenesis
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16209tion) for the primary mouse monoclonal antibodies and primary
antibody incubation was performed at 4uC overnight. The
immunohistochemical detection was performed using secondary
antibody horseradish peroxidase-labelled polymer and DAB
reagent (DakoCytomation). Immunofluorescent detection was
performed by anti-rabbit AlexaFluor 488 and anti-mouse Alexa-
Fluor 594 secondary antibodies (Invitrogen). The sources and
dilutions of the primary antibodies used for immunohistochemical
analysis were: mouse monoclonal Ki67, 1:1000 (Vector Labora-
tories), rabbit polyclonal phospho-AKT
Ser473(1:50), rabbit poly-
clonal IHC-specific phospho- mTOR
Ser 2448(1:100), phospho-
ribosomal S6 protein
Ser 240/244 (1:100), Caspase-3 (1:100) all four
from Cell Signalling, rabbit polyclonal GLUT1 (1:250) and rabbit
polyclonal Snail (1:250) from Abcam (1:250), mouse monoclonal
E-cadherin (1:100) from BD Biosciences, rabbit polyclonal ZO-1
(1:50) from Zymed (1:50), rabbit polyclonal Vimentin (1:250) and
goat phospho-Smad 2/3
Ser423/425 (1:500) from Santa Cruz.
Results
Lkb1 and Pten deletion from the mouse urothelium
We crossed mice bearing an inducible AhCreER
TM transgene [40]
with mice bearing a LoxP flanked Lkb1 cDNA cassette [38]; and with
m i c ec a r r y i n gaL o x Pf l a n k e dPten locus (exons 4 and 5, [39]). The
AhCreER
TM transgene is conditional, being induced by exposure to
beta-napthoflavone. Activity of the transgene is also tamoxifen
dependent, as the Cre recombinase protein is fused with an estrogen
receptor element [40]. This strategy drives extensive recombination in
the small intestine, liver and bladder with lesser efficiency in stomach
and gallbladder [40]. We generated four cohorts of mice, namely (a)
AhCreER
+Lkb1
fl/fl,( b )AhCreER
+Pten
fl/fl,( c )AhCreER
+Lkb1
fl/flPten
fl/fl and
(d) AhCreER-negative Lkb1
fl/flPten
fl/fl mice as a control cohort. Six week
old mice from all four cohorts were given a series of intraperitoneal
injections of beta-napthoflavone combined with tamoxifen (four
injections in two days, 12 hours between each of the two injections).
Beta-naphthoflavone induced Cre recombinase expression, and
tamoxifen induced the translocation of Cre into the nucleus [40].
To determine the extent of recombination, we also introduced the
LacZ Rosa reporter allele into a subset of animals [37]. As we have
previously shown, this protocol resulted in high efficiency recombi-
nation in the range of mouse epithelia [40]. However, given the
primary bladder phenotype (see below) we also now characterised
recombination levels within bladder urothelium, which revealed
extensive recombination in all cohorts (Fig. 1, A). To confirm gene
deletion and reduced protein expression within bladder urothelium,
we analysed levels of Lkb1 and Pten by western blot 50 days following
induction. AhCreER-negative Lkb1
fl/flPten
fl/fl (WT mice) showed Lkb1
and Pten proteins present (Fig. 1, B, lanes 1,2), AhCreER
+Pten
fl/fl
(Pten-deficient mice) showed reduced Pten protein levels (Fig. 1, B,
lanes 3,4), AhCreER
+Lkb1
fl/fl(Lkb1-deficient mice) showed decreased
Lkb1 protein levels (Fig. 1, B, lanes 5,6) and AhCreER
+Lkb1
fl/flPten
fl/fl
(Lkb1/Pten-deficient mice) had reduced Lkb1 and Pten levels (Fig. 1,
B, lanes 7,8).
Combined deletion of Lkb1 and Pten in the mouse
urothelium changes its morphology and proliferation
levels and promotes tumorigenesis
Twenty-five mice from each cohort group were aged to
investigate tumour incidence and survival. To further investigate
the disease process, we also examined bladder phenotypes in a
minimum of three animals from each genotype at days 50, 100
and 125.
Examination of bladder tissue revealed that Pten-deficient
bladders and Lkb1-deficient bladders did not show any significant
morphological differences from WT counterparts at day 50 (Fig. S1)
as well as at day 100 (Fig. 1, C). In contrast, Lkb1/Pten-deficient
mice showed a dramatic change in urothelial morphology,
epithelium appeared thicker, with more mitotic cells both at day
50 (Fig. S1) and 100 (Fig. 1, C). At day 50 thickness of urothelium
was 17.561.8 mm for WT, 19.561.6 mm for Pten-deficient,
16.062.1 mm for Lkb1-deficient and 58.565.4 mm for Lkb1/Pten-
deficient urothelium. We did not observe urothelial hyperplasia
detected at a similar timepoint (8weeks)inPten-deficient urothelium
described earlier [34] and this discrepancy may be due to some
differences in the genetic background of the experimental mice.
Bladder epithelium with Lkb1/Pten double deletion also exhibited
signs of impaired survival as assessed by the presence of apoptotic
bodies and vacuoles containing cellular debris both at day 50 (Fig.
S1) and day 100 (Fig. 1,C). We also performed Caspase-3staining at
day 100 to confirm that these are true apoptotic cells (Fig. S2).
By day 100 the mucosa of Lkb1/Pten -deficient bladders
appeared thickened, the urothelium was diffusely hyperplasic and
showed focal papillary growths with fine branching fibro-vascular
cores and atypical epithelium 5 to 12 cells thick.(Fig. 1, C, Fig. 2, B).
By day 125, the cohort developed large papillary tumours which
showed some tissue heterogeneity: it had tissue with vacuoles and
apoptotic cells as well as much denser tissue lacking them (Fig. 2,
C). This dense tissue showed no signs of apoptosis according to
Caspase-3 staining suggesting that the survival disadvantage is not
longer present in Lkb1/Pten-deficient bladder (Fig. S2). The tissue
showed signs of spindle-shaped cells, squamous metaplasia, focal
microvesicular change and a marked increase in nuclear-
cytoplasmic ratio (Fig. 2, C). Nuclei were enlarged, pleomorphic
and contained prominent nucleoli (Fig. 2, C). Neither day 100 nor
day 125 tumours showed evidence of invasion of the lamina
propria. Lkb1-deficient and Pten-deficient mice did not develop
bladder tumours in the long term. Lkb1-deficient mice developed
gastric polyps similar to those previously described [42], the onset
of which was 270 days after induction Mice were killed shortly
after this point and no bladder tumours were observed in these
animals. Pten-deficient mice also did not develop bladder tumours
at all the available timepoints (up to day 700).
After day 100 we noticed a marked decrease in Lkb1/Pten-
deficient cohort survival compared to WT, Lkb1-deficient and
Pten-deficient cohorts. The majority of Lkb1/Pten-deficient
animals became ill due to bladder blockage and they were
therefore culled during the following 50 days (Fig. 3, C). Bladders
from Lkb1-deficient and Pten-deficient cohorts of mice were not
different in size from the Cre-negative cohort but Lkb1/Pten-
deficient cohort bladders were enlarged, being 15.363.6 mm
diameter by day 125 post-induction (the size of WT mouse bladder
is 4.860.7 mm).
Urothelium with only Lkb1 deletion or only Pten deletion did
not show any changes in proliferation compared to WT according
to Ki67 staining (Fig. 3, A). WT urothelium had 0.3860.07%
Ki67-positive cells while Lkb1-deficient and Pten-deficient have
0.4160.05% and 0.4060.08%. By contrast, the deletion of both
Lkb1 and Pten led to an increase in proliferation levels. Before
induction, Lkb1/Pten
fl/fl bladders had 0.3660.04% Ki67-positive
cells but this figure rose to 19.3963.3% by day 30 according to
Ki67 staining (Fig. 3, A, B). The level of proliferation remained
relatively stable until day 100 (20.9863.1%), after which time a
further elevation was observed, reaching 46.4365.1% by day 125
(Fig. 3, B). After day 100, morphologically new structures were
identifiable in the urothelium: these were highly proliferative
areas with increased nucleus to cytoplasm ratio and they did not
contain vesicles with cellular debris typical of the initial stage of
tumorigenesis (Fig. 3, A).
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TM transgene used
here also drives recombination in other tissues, including stomach
and small intestinal epithelium. In this study, the primary
phenotype was observed in the bladder, and indeed all animals
had to be killed as a direct consequence of bladder tumorigenesis
and obstructed flow of urine. Our current data therefore indicates
a particularly strong synergy between Lkb1 and Pten in this
epithelial cell type.
Lkb1 and Pten show cooperative action in control of the
mTOR pathway in mouse urothelium
Combined deletion of Lkb1 and Pten led to a significant
increase in levels of phosphorylated mTOR
S2448 and S6 ribosomal
protein
S240/244 according to western blot (Fig. 1, B). Immunohis-
tochemical staining showed that the increase in mTOR
S2448 and
pS6
S40/244 ribosomal protein (Fig. 4) occurred only in the
epithelial layer of the mouse bladder of Lkb1/Pten-deficient mice.
At the same time, urothelium deficient in only Lkb1 or Pten did
not differ from WT in either mTOR
S2448 or pS6
S240/244 levels on
a western blot (Fig. 1, B) and mTOR
S2448 levels were only
marginally higher in Lkb1 and Pten single mutants according to
immunohistochemistry (Fig. 4A). No change was observed for
pS6
S240/244 (Fig. 4B).
Pten opposes the action of PI3K by dephosphorylating PIP3
and inhibiting the plasma membrane recruitment and phosphor-
ylation of Akt [19]. We examined AKT phosphorylation on
Ser473 as this strongly corresponds to Akt activation and occurs
frequently in aggressive tumours [43]. AKT
Ser473 levels were
elevated in Lkb1/Pten-double negative urothelium (Fig. 5, A) in
comparison with WT, Lkb1-deficient or Pten-deficient urothelium
(we did not observe any difference in AKT
Ser473 levels between
these latter three cohorts).
It is known that Lkb1 mediates its inhibitory role on the mTOR
pathway via phosphorylation of AMPK on Thr172 and subsequent
TSC2 phosphorylation on T1227 and S1345 [6]. We therefore
analysed levels of AMPK phosphorylation and found decreased
AMPK
Thr172 in both Lkb1-deficient and Pten/Lkb1-deficient
mouse urothelia according western blot (Fig. 1, B). Levels of
Ser
722phosphorylation of RaptoralsoreflectedAMPKactivationin
accordance with a previous study [44]. Raptor was phosphorylated
Figure 1. Lkb1 and Pten loss in the epithelium of mouse bladder after AhERCre recombinase induction. A, Cre-mediated recombination
is marked by beta-galactosidase reporter gene expression in mouse bladder. AhERCre-positive bladder tissue (Pten -deficient) shows extensive
recombination on day 14 after a regime of beta-naphtoflavone injections compared to no recombination in Cre-negative bladder tissue. B, Western
blot detection of Lkb1, Pten, phospho-AMPK (Thr172), phospho-mTOR (S2448), phospho-S6 ribosomal protein (S240/244), IRS-1 and phospho-IRS-1
(S307) expression in induced Cre-negative Lkb1
fl/fl Pten
fl/fl (1, 2) and induced Cre-positive: Pten
fl/fl bladder epithelial tissue (3,4), Lkb1
fl/fl bladder
epithelial tissue (5,6), Lkb1/Pten
fl/fl bladder epithelial tissue (7, 8) at day 50. C, Hematoxylin and eosin staining of bladder sections of Cre-negative
(WT) and recombined Cre
+ Pten
fl/fl, Cre
+Lkb1
f/fl, Cre
+ Pten
fl/flLkb1
fl/fl mice (both treated and non-treated with rapamycin) at day 100 following a
combined injection with beta-naphthoflavone and tamoxifen. Lkb1/Pten-deficient bladders show abnormal growth of urothelium which is
suppressed by rapamycin. Scale bars correspond to 400 mm (left column), 100 mm (middle column) and 20 mm (right column).
doi:10.1371/journal.pone.0016209.g001
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much less prominent in the samples from Lkb1 and Pten/Lkb1-
double deficient urothelium (Fig. 1, B). Unfortunately, anti-
TSC2
T1227 or anti-TSC2
S1345 antibodies are not available and we
not able to check the level of TSC2 phosphorylation on AMPK-
dependent sites. TSC1 and TSC2 protein levels were not affected in
all the four cohorts (data not shown).
Finally, we assessed the levels of S302 phosphorylation of IRS-1
as an indicator of the inhibitory feedback loop from mTOR/S6K
which suppresses insulin signaling to PI3K [45]. This phosphor-
ylation was the reason why insulin failed to activate AKT in
TSC2-deficient cells [45]. We observed a slight increase in
IRS-1
S302 phosphorylation in Lkb1-deficient bladders and a strong
increase in the double Lkb1/Pten bladder epithelium (Fig. 1, B).
We did not observe a decrease in the overall IRS-1 expression
(Fig. 1, B). We speculate that IRS-1 suppression in Lkb1-deficient
urothelium may lead to a negative feedback suppression of Akt
similarly to that observed in TSC2-deficient cells [45]. Wild type
levels of activated Akt are low (Fig. 5, A) so it was not possible to
assess its possible downregulation in Lkb1-deficient bladder.
Levels of mTOR phosphorylation in Lkb1-deficient urothelium
appeared marginally higher than in WT by immunohistochem-
istry (Fig. 4, A). However, western blot detection was insufficiently
sensitive to confirm any such increase (Fig. 1, B).
Figure 2. Bladder tumorigenesis after combined Lkb1 and Pten deletion. A-C, Hematoxylin and eosin staining of bladder sections of Cre-
negative (A) and bladder tumour in recombined Cre
+ Pten
fl/flLkb1
fl/fl mice at day 100 (B) and day 125 (C) following combined injection with beta-
naphthoflavone and tamoxifen. Borderlines show different areas of the tumour: more proliferative section is to the left and less proliferative
(containing vesicles) is inside the marked area. Scale bars correspond to 100 mm.
doi:10.1371/journal.pone.0016209.g002
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coincides with increased expression of the hypoxia
marker GLUT1
Since AKT/PI3K/mTOR pathway regulation is implicated in
hypoxia [23–28] we examined the expression of glucose transport-
er-1 protein (GLUT1), which has been reported to mark hypoxia in
human bladder cancer [46] and functions as part of the glucose
uptake machinery dependent on TSC2 phosphorylation and TSC
inhibition of mTOR [47]. GLUT1 expression was strongly elevated
in Lkb1/Pten -double negative urothelium in comparison with WT,
Lkb1-deficient or Pten -deficient urothelium (Fig. 5, B). This protein
is not normally expressed in the human bladder epithelium but it is
present in malignant bladder and especially in muscle-invasive
tumours when compared to superficial tumours [48].
Rapamycin suppresses the effects of combined Pten and
Lkb1 deletion in mouse urothelium
Since Lkb1 and Pten converge in mTOR control and given that
deletion of these proteins drastically changes bladder tissue
morphology we decided to confirm that the physiological effect
of this simultaneous deletion was mediated by via mTOR. We
therefore inhibited mTOR in the mouse bladder by exposure to
rapamycin and determined the effect upon phenotype. For each
genotype, ten animals were treated with vehicle and a further ten
animals were treated with 1 mg/kg of rapamycin intraperitoneally
every two days from day 50 onwards until day 100 when all the
animals were sacrificed.
Tissue examination revealed that the bladder epithelium of
rapamycin-treated WT, Pten -deficient and Lkb1-deficient
animals showed no change in comparison to both vehicle-treated
and untreated counterparts (data not shown). At the same time the
regime of rapamycin injections had a substantial impact on Lkb1/
Pten -deficient bladder. Rapamycin-treated Lkb1/Pten-deficient
bladders were 5.161.2 mm in diameter whereas vehicle-treated
were 14.664.1 mm. Rapamycin-treated Lkb1/Pten-deficient
epithelium showed reduced thickness in comparison with non-
treated, it had less mitotic cells whereas it retained some cells with
apoptotic bodies and vacuoles (Fig. 1, C). Caspase-3 staining did
not show an increase in apoptosis in rapamycin-treated Pten/
Figure 3. The combined loss of PTEN and Lkb1 induces bladder epithelium hyperproliferation and affects longevity.
A, Immunohistochemical staining with anti-Ki67 antibody showing proliferative cells in the bladder epithelium of Cre-negative and recombined
Cre
+Pten
fl/fl, Cre
+Lkb1
f/fl, Cre
+ Pten
fl/flLkb1
fl/fl mice (day 50 for all four genotypes and both days 50 and 125 for double-negatives) B, A graph showing the
increase in proliferative cellsin the bladder epithelium of Cre
+ Pten
fl/flLkb1
fl/fl mice,C, Kaplan-Meierplot of WT (Cre
2 Pten
fl/flLkb1
fl/fl) cohort is represented
in black stars (n=25), Cre
+ Pten
fl/fl cohort is represented in green (n=25), Cre
+Lkb1
f/flcohort is represented in blue (n=25), Cre
+ Pten
fl/flLkb1
fl/flcohort
represented in red (n=25. Cre
+Pten
fl/flLkb1
fl/fl mice show decreased longevity, where 100% of the cohort did not survive past day 179, x
2 tests confirmed
that Cre
+Pten
fl/flLkb1
fl/fl mice exhibit a significantly reduced average survival compared with Cre-negative cohort (P,0.0001, x
2=44.6), while other two
cohorts do not show the same tendency: Cre
+Pten
fl/fl (P=0.556, x
2=0.347), and Cre
+Lkb1
fl/fl (P=0.083506 x
2=3.00). Scale bars correspond to 20 mm.
doi:10.1371/journal.pone.0016209.g003
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(Fig. S2). It therefore appears that the primary effect of rapamycin
was to reduce mitosis levels. Apoptosis levels were relatively
unaffected, although notably apoptosis levels were already very
substantial in the Pten/Lkb1-double deficient normal urothelium
(Fig. S2). The rapamycin-treated epithelium did not show
hyperplasia or any papillary growths typical for vehicle-treated
group (Fig. 1, C). Rapamycin treatment also strongly suppressed
all the signs of mTOR hyperactivation in Lkb1/Pten-deficient
bladders: phosphorylation of mTOR
S2448 as well as AKT
Ser473,
and S6 ribosomal protein
S240/244 (Fig. 4, 5). The expression of the
hypoxic marker GLUT1 was also reduced, consistent with the
direct involvement of mTOR in GLUT1 upregulation, and also
with the observation of TSC2-mediated control of mTOR driven
GLUT1 expression related to cell growth regulation [47]. Taken
together, our data show that the effect of combined Lkb1 and Pten
deletion are mediated via mTOR.
mTOR activation in mouse bladder resulted in
characteristic features of epithelial-mesenchymal
transition (EMT)
The repression of both adherens and tight junction adhesion
proteins is associated with EMT [49,50]. Hence, expression levels
of the cell adhesion marker E-cadherin correlates with stage,
aggressiveness and progression of bladder cancer as well as
survival [51–55]. Similarly, Zonula occludens 1 (ZO-1) is a tight
junction marker which is lost during EMT induced by overactive
Figure 4. mTOR/S6K pathway deregulation in Lkb1/Pten-deficient mouse urothelium. The combined deletion of Lkb1 and Pten in the
mouse urothelium led to drastic changes in mTOR/S6K pathway by day 100 after the induction and this is prevented by rapamycin treatment.
A, B- Phospho- mTOR
Ser2448 (A) and Phospho- ribosomal S6 protein
Ser240/244 (B) immunostaining displaying elevated levels of mTOR and phosho-S6
ribosomal protein phosphorylation, Scale bars correspond to 50 mm.
doi:10.1371/journal.pone.0016209.g004
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performed immunofluorescent co-localization of both E-cadherin
and ZO-1 in the mouse bladder and showed that in WT, Lkb1-
deficient and Pten-deficient bladders they are both localised on the
cell membrane, with ZO-1 showing a more punctate pattern
marking tight junctions (Fig. 6, A). The simultaneous deletion of
Lkb1 and Pten leads to a drastic decrease in the expression of these
proteins whereas rapamycin treatment restores their expression
(Fig. 6, A).
The expression of both E-cadherin and other EMT markers is
controlled by Snail transcription factors and the ectopic expression
of Snail in epithelial cells causes them to acquire tumorigenic and
invasive properties [50]. High expression of Snail in human
bladder tumours is linked to the higher risk of cancer recurrence
[56]. We therefore analysed Snail expression in all our cohorts and
found that Snail nuclear localisation drastically increased in Lkb1/
Pten-double deficient epithelium and rapamycin treatment
suppresses it (Fig. 6, B).
The observed disappearance of E-cadherin and ZO-1 from cell-
cell junctions as well as the drastic rise in Snail nuclear localisation
suggests that Lkb1/Pten-deficient tissue might have acquired
mesenchymal properties. Vimentin is the most commonly used
Figure 5. Increased Akt phosphorylation and hypoxia in Lkb1/Pten-deficient mouse urothelium. The drastic changes in AKT/mTOR/S6K
pathway in Lkb1/Pten-double deficient urothelium corresponded to hypoxia marker GLUT1 upregulation by day 100 after the induction and this is
prevented by rapamycin treatment. A, B- Immunostaining showing a strong increase in Phospho-AKT
Ser473 (A) and GLUT1 (B) levels. Scale bars
correspond to 50 mm.
doi:10.1371/journal.pone.0016209.g005
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normally associated with EMT [57]. Immunostaining showed that
vimentin was not detectable in the urothelium of WT, Lkb1-
deficient and Pten-deficient mice, whereas Lkb1/Pten-double
deficient epithelium showed an increase in this marker (Fig. 6, B).
Particularly high vimentin levels were observed in a subset of cells
with spindle-shaped morphology typical for EMT (Fig. 6, B).
Bladders from rapamycin-treated Lkb1/Pten-double deficient
mice showed negligible vimentin staining similar to the other
three genotypes (Fig. 6, B). Our data therefore argue that
abnormally high mTOR signalling in Lkb1/Pten double deficient
bladders results in a switch in urothelial cell differentiation towards
a mesenchymal programme.
Discussion
EMT represents the first step towards invasion and metastasis
[12]. It is a complex mechanism that includes the remodeling of
cell adhesion, disassembly of tight junctions including the loss of E-
cadherin and ZO-1, and the transformation of polarized epithelial
cells into an elongated fibroblastoid mesenchymal phenotype
[12,15]. EMT can be initiated by a spectrum of mutations or
alterations in a range of signal transduction pathways and AKT/
PI3K pathway has suggested to be at the centre in this mechanism
[13], Here we report a new mouse model of bladder neoplasia
with combined deletion of two genes controlling AKT/PI3K/
mTOR pathway, Lkb1 and Pten in the urothelium (Fig. 1, A, B)
and we show that this pathway has a crucial role in EMT
occurring in this tissue (Fig. 6, A, B).
Pten deficiency is an important but not a sufficient factor in
bladder cancer. Although Pten expression is reduced in almost half
of human bladder cancer cases [29], only 10% of mice with
urothelial deletion of Pten have been reported to develop papillary
carcinomas [34]. Bladder tumours often have not just one but
several alterations in the expression of several components of
AKT/PI3K/mTOR pathway [29] suggesting the importance of
synergistic effect of different tumour suppressors. We therefore
hypothesized that tumorigenesis following loss of function of Pten
in the bladder may be dependent on the activity of other
mechanisms regulating mTOR. A very large proportion of
Figure 6. Lkb1/Pten-deficient mouse urothelium undergoes EMT. Mouse bladder epithelium deficient for both Lkb1 and Pten exhibits loss in
epithelial markers and acquire mesenchymal properties by day 100. Rapamycin inhibition of mTOR suppresses the observed effect. A, E-cadherin and
ZO-1 immunofluorescent co-localisation showing disappearance of these proteins from cell-cell walls in Lkb1/Pten-deficient bladder whereas
rapamycin treatment prevents this loss, B, Immunostaining showing a strong increase in Vimentin levels and Snail nuclear localisation after the
combined deletion of Lkb1 and Pten and this is mediated via mTOR evidenced from their suppressed levels in rapamycin-treated animals. Scale bars
correspond to 20 mm.
doi:10.1371/journal.pone.0016209.g006
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complex with TSC2 and its mutations were found in a number of
bladder cancer cases as well [29]. We aimed to investigate Pten
deficiency in the background of TSC1/2 downregulation.
Although Lkb1 was not previously linked with bladder cancer
and very few Lkb1 mutations were found in human bladder cancer
[29], this kinase is a known regulator of TSC1/2 complex via
AMPK and subsequent suppression of mTOR [6].
We tested whether Lkb1 deficiency alters tumorigenesis in a
Pten-deficient setting. To achieve this, we created several cohorts
of mice where either Lkb1 or Pten or both proteins were efficiently
deleted from mouse urothelium (Fig. 1A, B). Cohorts with single
Lkb1 or Pten deletions did not differ from WT but Lkb1/Pten
double deficient urothelium exhibited drastic changes in tissue
architecture (Fig. 1, C), tumorigenesis (Fig. 2) and proliferation
(Fig. 3, A, B) as well as compromised animal survival (Fig. 3, C).
Lkb1/Pten deficient urothelium exhibited hyperactivation of
mTOR/S6K pathway components: phospho-AKT
S473,
mTOR
S2448, phospho-S6
S240/244–ribosomal protein (Fig. 1, B,
Fig. 4, 5). Rapamycin treatment was an effective tool to suppress
this rise in mTOR signalling (Fig. 4) and it also suppressed other
mTOR-driven events occurring in Lkb1/Pten deficient urothe-
lium: EMT (Fig. 6, A, B) as well as hypoxia marker GLUT1
expression (Fig. 5B). We did not observe elevated levels of
components of mTOR/S6K pathway in case of single Pten or
Lkb1 deletion in the bladder, however we show that Lkb1 deletion
led to increased Ser302 phosphorylation of IRS-1 (equivalent to
human Ser307 residue) by p70S6K (Fig. 1, B). This suggests that,
in the absence of Lkb1, there was at least partial activation of the
feedback mechanism suppressing insulin signaling to PI3K which
may account for the lack of any observed phenotypic change in the
single mutants.
Why Lkb1 sporadic mutations are not common in human
bladder cancer [29] is an outstanding question considering both
our findings as well as its known function in regulating TSC1/2
complex [6]. It remains possible that Lkb1 is epigenetically
repressed, although we are currently not aware of any reports
supporting this. Alternatively, it may be possible that in the human
bladder, loss of Lkb1 results in a cellular survival disadvantage due
to increased sensitivity to metabolic stress, and that this precludes
LKB1 driven tumorigenesis. Clearly, in the mouse urothelium any
such disadvantage is insufficient to block tumorigenesis, although
of note we did observe an increase in apoptosis in Lkb1/Pten-
deficient urothelium (Fig. S2). In the light of this a double cross of
Pten with Tsc1 (or Tsc2) may clarify the mechanism of bladder
tumorigenesis.
Our observations correspond to the previous findings about
AKT/PI3K/mTOR pathway involvement in EMT in other
tissues and organs [12–14]. In our model the combined deletion of
both Lkb1 and Pten in the mouse bladder drastically activates
mTOR pathway and this precise activation serves as a signal for
EMT program execution (Fig. 6). When mTOR was suppressed
with rapamycin injections, bladders showed no signs of EMT
(Fig. 6). Lkb1/Pten doubly deficient bladder exhibited loss of both
adherence (E-cadherin) and tight junction (ZO-1) markers (Fig. 6,
A), together with elevation of the nuclear localization of Snail
transcription factor and increase in Vimentin mesenchymal
marker (Fig. 6, B). The observed phenotype also included
elevation of the hypoxia marker GLUT1 and this also was due
to deregulated mTOR since rapamycin injections prevented
GLUT1 upregulation (Fig. 5, B). Tumour hypoxia is usually a
sign of poor prognosis and resistance to radiation therapy [57] and
hypoxic conditions can be a prerequisite to EMT and conse-
quently can lead to invasion metastasis [58, 59]. We did not
observe invasion in our model but we realize that our time frame
could be insufficient; with tumours developing rapidly.
The inhibition of EMT by rapamycin (Fig. 6) argues that the
bladder phenotype is primarily due to elevated mTOR activity;
however it has been shown by others that EMT can be controlled
by a complex variety of signal transduction pathways [15–18].
Clearly, it will be interesting to investigate possible cross-talk
between mTOR and these other pathways in EMT induction,
particularly with TGF-b since it cooperates with mTOR in EMT
induction [21].
mTOR hyperactivation in the mouse bladder led to a combina-
tion of EMT and abnormal proliferation. Normal bladder
epithelium is known to be a slowly proliferating tissue (unless
injured), with the complete renewal of the urothelial cell population
taking the whole lifespan of the mouse [60]. Cell proliferation in
either Pten or Lkb1 deficient epithelia remained low as shown by
Ki67 immunostaining, with no overt proliferative advantage
following gene deletion (Fig. 3, A). The morphology in Pten and
Lkb1-deficient epithelium was also not changed (Fig. 1, C). When
Pten and Lkb1 were deleted in murine urothelium simultaneously,
this invariably resulted in hyperproliferation and hyperplasia in all
the animals from the Lkb1/Pten-deficient cohort. These effects on
bladder growth were truly mediated by mTOR since rapamycin
treatment prevented all the signs of hyperplasia. Rapamycin did not
enhance apoptosis in Pten/Lkb1-deficient urothelium (Fig. S2) but
acted as the suppressor of mTOR-mediated cell growth similarly to
the urothelial model of Pten/p53 deficiency [36]. The simultaneous
deletion of Lkb1 and Pten in the mouse bladder resulted in diffusely
hyperplasic atypical urothelium with papillary growths and the
tumourswerehistologicallysimilartohumanneoplasms:byday100
resembled a low grade papillary urothelial carcinoma and turned
into high grade by day 125 [61]. By day 125 the morphology of the
tumours altered, such that they appeared more dense and
proliferative (Fig. 2, C). This coincided with a decrease in animal
survival due to bladder obstruction. Apart from the synergy in the
bladder we also observed some effects of simultaneous deletion of
Lkb1 and Pten on cell proliferation in the pyloric section of the
stomach (data not shown). Small intestines of Lkb1/Pten-deficient
mice did not however develop tumours despite extensive recombi-
nation in that tissue, with the epithelium showed a similar
phenotype to that described previously for the single mutants
[62,63]. We therefore speculate that the mode of regulation of
mTOR is tissue-specific and is perhaps more tightly regulated in
highly proliferative tissues (such as the small intestine), as opposed to
the less proliferative bladder.
We show here for the first time the phenotype of homozygous
deletion of both Lkb1 and Pten in a given epithelium and
demonstrate clear synergy in mTOR control in mouse urothelium,
a synergy which normally leads to tumour suppression in this
tissue. We conclude that altered mTOR leads to EMT and
tumorigenesis in the mouse bladder. The data show the necessity
of tight control of PI3K/AKT/mTOR pathway in the mouse
bladder and also suggest that the mouse bladder can be a useful
model for EMT-related research.
Supporting Information
Figure S1 Hematoxylin and eosin staining of bladder
sections of Cre-negative and recombined Cre
+Pten
fl/fl,
Cre
+Lkb1
f/fl, Cre
+Pten
fl/flLkb1
fl/fl mice at day 50 follow-
ing a combined injection with beta-naphthoflavone and
tamoxifen. Scale bars correspond to 500 mm (left column) and
100 mm (right column).
(TIF)
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hibits Caspase-3 elevation up to day 100 and with zones
devoid of apoptosis appearing at the later stages (day
125). Rapamycin inhibition of mTOR suppresses apoptosis. Scale
bars correspond to 50 mm.
(TIF)
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